HBIO Logo

Harvard Bioscience, Inc. (HBIO) 

NASDAQ
Market Cap
$116.88M
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
247 of 776
Rank in Industry
19 of 48

Largest Insider Buys in Sector

HBIO Stock Price History Chart

HBIO Stock Performance

About Harvard Bioscience, Inc.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate …

Insider Activity of Harvard Bioscience, Inc.

Over the last 12 months, insiders at Harvard Bioscience, Inc. have bought $90,500 and sold $0 worth of Harvard Bioscience, Inc. stock.

On average, over the past 5 years, insiders at Harvard Bioscience, Inc. have bought $251,977 and sold $1.16M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Green James W (Chief Executive Officer) — $181,000.

The last purchase of 10,000 shares for transaction amount of $29,100 was made by Green James W (Chief Executive Officer) on 2024‑06‑13.

List of Insider Buy and Sell Transactions, Harvard Bioscience, Inc.

2024-06-13PurchaseChief Executive Officer
10,000
0.0242%
$2.91$29,100-2.41%
2024-06-06PurchaseChief Executive Officer
20,000
0.0474%
$3.07$61,400-4.70%
2023-08-17PurchaseChief Executive Officer
25,000
0.06%
$4.38$109,500-1.39%
2023-03-15PurchaseChief Executive Officer
20,000
0.0468%
$2.60$52,000+71.21%
2023-03-15Purchasedirector
16,192
0.0382%
$2.62$42,423+71.21%
2023-03-14PurchaseChief Executive Officer
20,000
0.0475%
$2.67$53,400+69.29%
2023-03-14Purchasedirector
13,808
0.0328%
$2.67$36,867+69.29%
2022-12-01PurchaseChief Executive Officer
15,000
0.0341%
$2.61$39,150+54.15%
2022-11-30PurchaseChief Executive Officer
15,000
0.0341%
$2.41$36,150+66.60%
2022-08-26Purchase
9,291
0.0231%
$3.41$31,682-5.78%
2022-08-24Purchase
8,244
0.0207%
$3.34$27,535-2.82%
2022-08-22Purchase
4,918
0.0118%
$3.16$15,541-2.21%
2022-08-18Purchase
1,151
0.0028%
$3.19$3,672-2.52%
2022-08-17PurchaseChief Executive Officer
40,000
0.0961%
$3.19$127,600-2.82%
2022-06-15PurchaseChief Executive Officer
30,000
0.0734%
$3.71$111,300-15.53%
2022-05-06PurchaseChief Executive Officer
10,000
0.0219%
$3.40$34,000-17.55%
2021-08-23SaleChief Executive Officer
48,175
0.1175%
$8.02$386,364-26.02%
2021-05-21SaleChief Executive Officer
24,312
0.0605%
$7.14$173,588-2.52%
2021-05-20SaleChief Executive Officer
14,876
0.0372%
$7.03$104,578-0.43%
2021-05-18SaleChief Executive Officer
39,188
0.0988%
$7.41$290,383-4.37%

Insider Historical Profitability

15.47%
Green James WChief Executive Officer
3111091
7.1337%
$2.68165+24.69%
Skystone Advisors LLC10 percent owner
3744819
8.5869%
$2.68645+9.98%
GRAZIANO CHANE10 percent owner
3105150
7.1201%
$2.6850+21.41%
HSO LIMITED PARTNERSHIP10 percent owner
2757257
6.3224%
$2.68402+8.24%
GREEN DAVIDdirector
925571
2.1223%
$2.681573+46.82%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
B Riley Asset Management Llc$12.02M6.532.83M-3.55%-$442,388.894.94
BlackRock$12.01M6.532.83M-2.75%-$339,836.02<0.0001
Punch & Associates Investment Management, Inc.$11.75M6.382.77M-4.99%-$617,746.780.68
Harvey Partners$10.84M5.892.56M0%+$01.21
Amh Equity Ltd$9.85M5.352.32M+7.46%+$683,941.6812.77
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.